TECX Fundamental Analysis - TECTONIC THERAPEUTIC INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to TECX. TECX was compared to 538 industry peers in the Biotechnology industry. While TECX seems to be doing ok healthwise, there are quite some concerns on its profitability. TECX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year TECX has reported negative net income.

TECX had a negative operating cash flow in the past year.

TECX had negative earnings in each of the past 5 years.

TECX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -22.34%, TECX is in the better half of the industry, outperforming 74.91% of the companies in the same industry.

The Return On Equity of TECX (-23.25%) is better than 82.53% of its industry peers.

		Industry Rank	Sector Rank
ROA	-22.34%
ROE	-23.25%
ROIC	N/A

ROA(3y)-71.59%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TECX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TECX has more shares outstanding than it did 1 year ago.

TECX has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 14.00 indicates that TECX is not in any danger for bankruptcy at the moment.

The Altman-Z score of TECX (14.00) is better than 88.66% of its industry peers.

TECX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.

TECX has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: TECX outperforms 50.19% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	14

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

TECX has a Current Ratio of 25.60. This indicates that TECX is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of TECX (25.60) is better than 96.84% of its industry peers.

A Quick Ratio of 25.60 indicates that TECX has no problem at all paying its short term obligations.

TECX's Quick ratio of 25.60 is amongst the best of the industry. TECX outperforms 96.84% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	25.6
Quick Ratio	25.6

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

TECX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.01%, which is quite impressive.

EPS 1Y (TTM)55.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%75.35%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

TECX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.23% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y47.86%

EPS Next 2Y17.87%

EPS Next 3Y8.23%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TECX. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TECX. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y17.87%

EPS Next 3Y8.23%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TECX does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TECTONIC THERAPEUTIC INC

NASDAQ:TECX (9/25/2025, 6:35:36 PM)

After market: 14.71 0 (0%)

14.71

-0.28 (-1.87%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-07 2025-08-07/amc

Earnings (Next)11-05 2025-11-05/bmo

Inst Owners60.22%

Inst Owner Change10.32%

Ins Owners27.3%

Ins Owner Change2.24%

Market Cap275.22M

Analysts82.86

Price Target81.35 (453.03%)

Short Float %22.38%

Short Ratio8.1

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)4.84%

Min EPS beat(2)-6.86%

Max EPS beat(2)16.54%

EPS beat(4)2

Avg EPS beat(4)1.92%

Min EPS beat(4)-42.6%

Max EPS beat(4)40.61%

EPS beat(8)4

Avg EPS beat(8)-15.91%

EPS beat(12)5

Avg EPS beat(12)-43.44%

EPS beat(16)7

Avg EPS beat(16)-32.91%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-0.73%

PT rev (3m)-3.63%

EPS NQ rev (1m)0.43%

EPS NQ rev (3m)-3%

EPS NY rev (1m)0%

EPS NY rev (3m)-1.93%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	0.97
P/tB	0.97
EV/EBITDA	N/A

EPS(TTM)-4.04

EYN/A

EPS(NY)-5

Fwd EYN/A

FCF(TTM)-3.44

FCFYN/A

OCF(TTM)-3.43

OCFYN/A

SpS0

BVpS15.17

TBVpS15.17

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-22.34%
ROE	-23.25%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-71.59%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	11.21%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	25.6
Quick Ratio	25.6
Altman-Z	14

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)78.64%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)55.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%75.35%

EPS Next Y47.86%

EPS Next 2Y17.87%

EPS Next 3Y8.23%

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-34.75%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-22.46%

EBIT Next 3Y-17.63%

EBIT Next 5YN/A

FCF growth 1Y-44.62%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-45.23%

OCF growth 3YN/A

OCF growth 5YN/A

TECTONIC THERAPEUTIC INC (TECX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens